Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380987 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL890411 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL27340865 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL14829522 | 0.87 | CYP2C19 (0.41) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL14829268 | 0.87 | CYP2C19 (0.41) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL2154406 | 0.85 | ACE (0.36) | LMNACES2CES1 | |
| SCHEMBL11820398 | 0.85 | — | — | |
| SCHEMBL11819070 | 0.82 | — | — | |
| SCHEMBL3795815 | 0.82 | GABRR1 (0.30) | — | |
| SCHEMBL4029521 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 630 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616948-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2026-05-05 | — | — | US | claimed |
| US-12594529-B2 | Preparation method of Ti3C2TX MXene quantum dot (MQD)-modified polyamide (PA) reverse-osmosis (RO) membrane | RESEARCH INSTITUTE OF CHEMICAL DEFENSE, PLA ACADEMY OF MILITARY SCIENCES (CN) | 2026-04-07 | — | — | US | claimed |
| US-12508565-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2025-12-30 | — | — | US | claimed |
| EP-4616929-A1 | POLYAMIDE COMPOSITE MEMBRANE AND PREPARATION METHOD THEREFOR | Wanhua Chemical Group Co., Ltd. (CN) | 2025-09-17 | — | — | EP | claimed |
| CN-119857376-A | Oxidation-resistant seawater desalination reverse osmosis membrane, preparation method and application thereof | 万华化学集团股份有限公司 | 2025-04-22 | — | — | CN | claimed |
| US-20240375074-A9 | POLYAMIDE MICROCAPSULES | FIRMENICH & CIE (CH) | 2024-11-14 | — | — | US | claimed |
| WO-2024174089-A1 | POLYAMIDE COMPOSITE MEMBRANE AND PREPARATION METHOD THEREFOR | 万华化学集团股份有限公司 | 2024-08-29 | — | — | WO | claimed |
| US-20240207793-A1 | PREPARATION METHOD OF TI3C2TX MXENE QUANTUM DOT (MQD)-MODIFIED POLYAMIDE (PA) REVERSE-OSMOSIS (RO) MEMBRANE | RESEARCH INSTITUTE OF CHEMICAL DEFENSE, PLA ACADEMY OF MILITARY SCIENCES (CN) | 2024-06-27 | — | — | US | claimed |
| US-20240050330-A1 | PROCESS FOR PREPARING POLYESTER MICROCAPSULES | FIRMENICH SA (CH) | 2024-02-15 | — | — | US | claimed |
| US-20240050917-A1 | PROCESS FOR PREPARING POLYESTER MICROCAPSULES | FIRMENICH SA (CH) | 2024-02-15 | — | — | US | claimed |
| EP-0242878-B1 | COMPOSITE MEMBRANE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-09 | — | — | EP | claimed |
| US-4812238-A | POLYAMIDES, REVERSE OSMOSIS | THE DOW CHEMICAL COMPANY (US) | 1989-03-14 | — | — | US | claimed |
| US-4719062-A | AQUEOUS SOLUTIONS OF LOWER ALKANOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-12 | — | — | US | claimed |
| EP-0242877-A1 | Extractant-surfactant posttreatments of permselective composite membranes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-28 | — | — | EP | claimed |
| EP-0242878-A1 | Composite membrane | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-28 | — | — | EP | claimed |
| EP-0219125-A2 | Coating process for composite reverse osmosis membranes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-22 | — | — | EP | claimed |
| US-4626468-A | Microporous support layer with interfacially polymerized copolyamide thereon | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-0170232-A2 | Production of composite membranes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-02-05 | — | — | EP | claimed |
| US-4529646-A | Polysulfone membrane | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| US-4520044-A | FORMING POLYAMIDE ON POLYSULFONE SUBSTRATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050330-A1 | PROCESS FOR PREPARING POLYESTER MICROCAPSULES | CHMP4B, EXOSC9, F5 | CYP2D6 2271/4885LMNA 2020/4885BLM 3637/4885 |
| US-20240050917-A1 | PROCESS FOR PREPARING POLYESTER MICROCAPSULES | CHMP4B, EXOSC9, F5 | CYP2D6 2271/4885LMNA 2020/4885BLM 3637/4885 |
| US-12508565-B2 | Polyamide microcapsules | PHGDH, GLUL, PCCA | CYP2D6 3356/4885LMNA 3353/4885BLM 4491/4885 |
| US-12594529-B2 | Preparation method of Ti3C2TX MXene quantum dot (MQD)-modified polyamide (PA) reverse-osmosis (RO) membrane | AQP3, AQP1, PUF60 | CYP2D6 4784/4885LMNA 964/4885BLM 1760/4885 |
| US-12616948-B2 | Polyamide microcapsules | HDHD5, DDC, USP39 | CYP2D6 4011/4885LMNA 3120/4885BLM 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.